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Background: Protein domains display a range of structural diversity, with numerous additions and deletions of
secondary structural elements between related domains. We have observed a small number of cases of surprising
large-scale deletions of core elements of structural domains. We propose a new concept called domain atrophy,
where protein domains lose a significant number of core structural elements.
Results: Here, we implement a new pipeline to systematically identify new cases of domain atrophy across all
known protein sequences. The output of this pipeline was carefully checked by hand, which filtered out partial domain
instances that were unlikely to represent true domain atrophy due to misannotations or un-annotated sequence
fragments. We identify 75 cases of domain atrophy, of which eight cases are found in a three-dimensional protein
structure and 67 cases have been inferred based on mapping to a known homologous structure. Domains with
structural variations include ancient folds such as the TIM-barrel and Rossmann folds. Most of these domains are
observed to show structural loss that does not affect their functional sites.
Conclusion: Our analysis has significantly increased the known cases of domain atrophy. We discuss specific instances
of domain atrophy and see that there has often been a compensatory mechanism that helps to maintain the stability
of the partial domain. Our study indicates that although domain atrophy is an extremely rare phenomenon, protein
domains under certain circumstances can tolerate extreme mutations giving rise to partial, but functional, domains.Background
Protein domains are independently evolving structural
and function units. These units have been recombined
in many ways creating proteins that perform diverse
functions. Proteins, in the course of evolution, may ac-
quire (domain gain) or lose (domain loss) one or more
entire domains by a variety of means [1,2]. At a smaller
scale of modification, protein domains can gain or lose
secondary structural elements through insertion or dele-
tion of amino acid residues. Insertions or deletions are
known to significantly influence protein folding [3] and
are considered important evolutionary factors which in-
fluence protein structure and function [4]. Proteins and
their domains are only marginally stable, such that the
mutation of a single residue may be sufficient to induce
the unfolding of the domain. Single point mutations can
lead to a large range of human diseases. However,* Correspondence: agb@ebi.ac.uk
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article, unless otherwise stated.through evolution a protein’s sequence is slowly changed
so that quite divergent sequences can give rise to a similar
three-dimensional (3D) structure. This means that proteins
are tolerant of small stepwise changes in their sequence.
Analyses of a large number of domain structures have
indicated significant variability in domain lengths [5].
These variations are mostly attributed to insertions or de-
letions in loops, coils or of a few secondary structural ele-
ments, leaving the domain core largely unaffected [5-7].
Cases of such domain length variations caused by gain of
accessory secondary structural elements or ‘embellish-
ments’ are well documented. Examples of the so-called
domain elaborations can be observed in the HUP super-
family [8], wherein embellishments influence interactions,
substrate binding and stability of the core domain.
Similar to domain elaborations, one could envisage
events leading to loss or degradation of a domain’s sec-
ondary structure elements necessitated by similar evo-
lutionary constraints as above. We propose the term
‘domain atrophy’ for events that lead to significant loss
of core secondary structure elements (Figure 1). SuchCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic representation of domain atrophy event. A protein domain in a particular architecture undergoes truncation due to mutation. A
protein with truncated domain that retains its functional role (structural or enzymatic) is positively selected, while a protein with non-viable truncated
domain is lost. Complete and incomplete domain boundaries are denoted by smooth and toothed edges, respectively. The dotted line in the toy
example at the right shows the region of upstream domain-bounded atrophy.
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in the ‘truncated globins’ [9], bacterial luciferases [10]
and recently in a domain of unknown function
DUF2172 [11].
It seems possible that the process of domain atrophy
occurs by a single large-scale mutation, which raises
the question of how can a protein tolerate such a large
destabilising event. Such events of loss of >10 amino
acid residues are more likely to be very destabilising.
Losses at protein termini are more likely to be toler-
ated, particularly if they are of peripheral secondary
structures. For example, partial deletion of the first
seven residues at the N-terminus of Ig-domain of the
human muscle protein titin only marginally decreased
its stability by 2.8 kcal/mol [12], however mutations
within the core are unlikely to be tolerated. Deletions
of many amino acids are normally unlikely to be toler-
ated unless they are found in a loop region. Therefore,
natural occurrences of stable protein domains with
large-scale deletions of core secondary structures
[10,11] are intriguing and suggest that compensatory
mechanisms that help stabilise these atrophied do-
mains must exist.
An alternative possibility is that a globular domain that
undergoes an atrophy event then becomes disordered
and may adopt some new function. We believe that we
are unlikely to be able to observe such events as thepattern of conservation is likely to significantly change
leading to very rapid sequence divergence. However, the
relationship of domain atrophy to protein disorder may
be an interesting avenue for future research.
Unlike domain elaboration, which is commonly seen
in protein structures, structural data and literature on
domain atrophy is very scarce. Using sequence based
protein-HMM models of domain families, we have de-
vised an algorithm to identify potential cases of domain
atrophy and have identified several new cases in proteins
of known structure. Where 3D structures of the atro-
phied domain were not available, we have used sequence
mapping onto reference complete domain structures to
infer potential domain atrophy events.
A companion paper by Triant and Pearson [13] de-
scribes several computational artefacts that can produce
partial domain instances, which may confound the dis-
covery of cases of domain atrophy. They show that do-
mains can appear short because they have been broken
up into pieces by the alignment process, or because they
are annotated on incorrectly assembled proteins, or be-
cause the Pfam domain models have been built from
two or more evolutionarily mobile domains. In this
paper, we use several strategies to avoid these biological
and computational artefacts, and identify a set of atro-
phied domains that are complementary to the ‘structural
partials’ identified by Triant and Pearson.
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In order to quantify the magnitude of structural loss we
have defined a metric called the Atrophy Score (see
Methods), which indicates the fraction of the domain
that is likely to be missing. It is based on looking at
matches of Pfam profile-HMMs to a sequence. For some
domains only part of the profile-HMM model may
match to the sequence. We use these partial matches to
identify where a protein domain is potentially atrophied.
The atrophy score is equivalent to the fraction of a Pfam
profile-HMM model that is missing from a protein do-
main. While a positive atrophy score indicates structural
loss, zero or negative atrophy scores indicate complete
domain boundaries, that is, no atrophy. We did not in-
vestigate instances with an atrophy score below 0.15,
where less than 15% of the domain is lost. Domains
showing this small level of atrophy are very likely to be
enriched in false positives where loss of peripheral sec-
ondary structures can be tolerated. A feature of the atro-
phy score is the possibility of scores to reach 1 or
higher. This can happen when one domain is nested
within another, leading to a negative inter-domain dis-
tance. These cases are excluded from our analysis.
A partial match to a Pfam profile-HMM is only weak
evidence for domain atrophy. As Triant and Pearson
show, even if a match to the whole HMM is not present
one can often find that the similarity can be extended to
the full domain length with a sequence similarity com-
parison. Therefore, we look in particular at partial do-
mains that are end bounded by either another domain,
or the terminus of the sequence.
We have categorised domain atrophy into five differ-
ent types that are fully described in the Methods section
(Figure 2). The five types are: (1) N-terminal end-Figure 2 The five classes of domain atrophy events. Complete domains ar
are represented with jagged-ended boundaries.bounded atrophy; (2) C-terminal end-bounded atrophy; (3)
Upstream domain-bounded atrophy; (4) Downstream
domain-bounded atrophy; and (v) Within-domain atrophy.
Domain instances that scored between 0.15 and 1 were
manually examined to identify potential false positive
cases (see Table 1). Manual inspection helped to discern
probable true cases of domain atrophy from possible
false positive cases. We were able to confirm eight cases,
which have a known structure and a further 67 cases
that belonged to a family where a homologous structure
was known. In the following section we discuss some ex-
amples of domain atrophy that we have discovered. A
full list of true and putative domain atrophy cases can be
found in Additional file 1.
N-terminal end-bounded atrophy
Bacterial luciferase domain (Pfam: PF00296)
The bacterial luciferase domain of the non-fluorescent
flavoprotein (NFP) from Photobacterium phosphoreum
LuxF (UniProt: P12745), shows an atrophy score of 0.31,
indicating a loss of nearly one-third of the domain’s
structure.
The bacterial luciferase domain, homolog of bacterial
luciferase subunits [14], is present mostly among mem-
bers of gammaproteobacteria. NFP is thought to func-
tion as a ‘molecular sponge’ by sequestering myristylated
flavine mononucleotide, the side-product of the bio-
luminescence pathway [14].
NFP of P. phosphoreum (PDB: 1FVP) resembles a
partial TIM-barrel-like fold with one β-strand and
three α-helices missing [15] (Figure 3A). The complete
structure of the bacterial luciferase domain from Bacillus
cereus (PDB: 2B81) was chosen as the reference domain
for comparison. The reference domain has a (β/α)8 TIM-e represented with round-ended boundaries and incomplete domains















Total 499 (100%) 468 (100%) 125 (100%) 331 (100%) 213 (100%)
Structure available True domain atrophy 6 (1.20%) 0 (0.00%) 0 (0.00%) 2 (0.60%) 0 (0.00%)
False positive 161 (32.26%) 119 (25.42%) 27 (21.60%) 104 (31.41%) 45 (21.13%)
Homologous structure available Putative domain atrophy 34 (6.81%) 26 (5.55%) 0 (0.00%) 3 (0.90%) 4 (1.88%)
False positive 216 (43.28%) 218 (46.58%) 91 (72.80%) 207 (62.53%) 99 (46.48%)
No structure available Unknown 82 (16.43%) 105 (22.43%) 7 (5.60%) 15 (4.53%) 65 (30.52%)
The table shows the breakdown of domain atrophy instances with atrophy scores between 0.15 and 1.
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structure consisting of eight alternating β-strands and
α-helices.
Although identified as N-terminal end-bounded atro-
phy, comparison with the reference domain (PDB: 2B81)
shows that β1, α1 and β2 of 2B81 structurally aligns with
the corresponding structural elements at the N-terminal
region of 1FVP. However α2, β3, α3 and α4, of the refer-
ence domain 2B81 (residues 61-125, 132-192), have no
corresponding matching structural elements on 1FVP.
This suggests that P. phosphoreum bacterial luciferase
domain is an example of within-domain atrophy rather
than N-terminal end-bounded atrophy as first thought.
We also identified a similar case of domain atrophy in
the orthologous protein of Photobacterium leiognathi
(UniProt: P09142, PDB: 1NFP).Figure 3 N-terminal end-bounded atrophy: Bacterial luciferase. (A) Monom
phosphoreum non-fluorescent flavoprotein (PDB: 1FVP, light green) bound to
(B) Monomer of the Bacillus cereus reference structure (PDB: 2B81, light blue).
domain atrophy is stabilised by the new dimer interface. (D) Homo-dimer comA key issue is in determining whether domain atrophy
has occurred is whether the ancestral fold of bacterial
luciferase domains was indeed a TIM-barrel. Phylogen-
etic analysis of bacterial luciferase family indicates that
the LuxF protein clade is completely enclosed by LuxB
(Figure 4) and that the ancestral fold must be the
complete TIM-barrel fold observed in the LuxB and
LuxA proteins.
Does the structure shed any light on how an atrophied
domain can tolerate a large deletion? The TIM-barrel
fold has a central hydrophobic β-barrel surrounded by
alpha helices, which shield the barrel from the solvent.
However, the monomeric structure of the atrophied
bacterial luciferase domain shows a barrel with a large
hydrophobic cleft apparently exposed to the solvent. The
atrophied domain buries this hydrophobic surface byer of the atrophied bacterial luciferase domain of Photobacterium
ligand FMA (6-(3-tetradecanoic acid) flavine mononucleotide, orange).
(C) Homo-dimer complex of 1FVP. The exposed hydrophobic core due to
plex of 2B81 showing dimerisation on the same side of the molecule.
Figure 4 A section of the phylogenetic tree of bacterial luciferase domains. The bacterial luciferase, non-fluorescent flavoprotein (LuxF) and the
alkanal monooxygenase beta (LuxB) share a common ancestor. The ancestral fold of luciferase is a complete TIM-barrel fold observed in LuxB and
LuxA proteins.
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(Figure 3C) [16,17]. The hydrophobic core residues thus
exposed by the atrophy event are stabilised by interac-
tions at the new dimer interface. We hypothesise that
such a compensatory mechanism may be a crucial factor
in the selection of the otherwise unstable atrophied do-
main. Interestingly bacterial luciferase, in its complete
form [18], also functions as a dimer in vivo and forms a
homo-dimer with the dimer interface being on the same
side of the molecule as observed in the atrophied
domain-dimers (Figure 3D).
AMP-binding domain (Pfam: PF00501)
The Adenosine monophosphate (AMP) binding domain
of phenylacetate-coenzymeA ligases from Burkholderia
cenocepacia (UniProt: B4E7B5) (Figure 5A), exhibits
structural loss at the N-terminus with an atrophy score of
0.16 corresponding to a loss of 67 amino acid residues.
Phenylacetate-coenzymeA ligases are adenylate-forming
enzymes, which are involved in the metabolism of pheny-
lacetate [19]. The enzyme links the phosphoryl moiety of
AMP to the carboxyl group of the substrate thereby acti-
vating it before transferring to the acceptor CoA [19].
The AMP-binding domain is present in proteins such as
acyl-CoA synthetases [20], aryl-CoA ligases [21], firefly
luciferases [22] and non-ribosomal peptide synthetases[23]. The N-terminal AMP-binding domain of the refer-
ence structure, 4-chlorobenzoyl CoA ligase from Alcali-
genes sp. (PDB: 3CW9), shows a large, globular, distorted
α/β structure comprising three distinct β-sheets with a
large cleft containing the binding pocket [24] (Figure 5B).
Structural superposition of the ‘N-terminal microdo-
mains’ of B. cenocepacia (PDB: 2Y27) [25] onto the ref-
erence structure (PDB: 3CW9) reveals a marked absence
of the first sub-domain (residues 1-150) (Figure 5C).
It can be seen from the reference structure that the
first sub-domain has minimal interactions with the sub-
strates during adenylation and the subsequent thioester
formation processes [24]. The homo-dimeric complex of
B. cenocepacia phenylacetate-coenzymeA ligase results
in the formation of an intramolecular β-sheet at the
dimer interface [25]. Interestingly this interaction, in-
volving the second sub-domains (residues 151-322),
forms an arrangement that is structurally similar to the
first sub-domain [25] (Figure 5D). Again a homo-dimeric
arrangement is used to ensure that residues exposed by
domain atrophy are buried thereby compensating for do-
main atrophy. The atrophied domain of B. cenocepacia is
thought to be functional and is involved in recruiting subse-
quent enzymes of the phenylacetic acid degradation path-
way [25]. In addition to atrophy observed in B. cenocepacia,
we find similar domain atrophies in the phenylacetate-
Figure 5 N-terminal end-bounded atrophy: AMP-binding domain. Comparison of (A) the atrophied N-terminal AMP-binding domain of B. cenocepacia
phenylacetate-CoA ligase (PDB: 2Y27, green) and (B) reference structure, Alcaligenes sp 4-chlorobenzoyl CoA ligase (PDB: 3CW9, blue) bound to AMP
(gold) and 4-Chlorophenacyl-coenzyme A (magenta). (C) Superposition of the N-terminal domains shows the atrophied region of 2Y27, which
corresponds to the first sub-domain of 3CW9 (orange, residues 1-150). The residues of the first sub-domain, except Arg87 (yellow), have
minimal interactions with ligands AMP (gold) or 4-Chlorophenacyl-coenzyme A. (D) Homo-dimeric complex of atrophied B. cenocepacia
phenylacetate-CoA ligase forms an arrangement, which at the interface is structurally similar to the first-sub domain.
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micron (UniProt: Q8AAN6, PDB: 3QOV) and the phena-
zine antibiotic biosynthesis protein from Enterobacter
agglomerans (UniProt: Q8GPH0, PDB: 3HGU).
C-terminal end-bounded atrophy
Ral-GTPase-activating protein domain (Pfam: PF02145)
The Ral-GTPase-activating protein (RapGAP) domain of
the rat Ral-GTPase-activating subunit α-1 (UniProt:
O55007) has a C-terminal atrophy score of 0.46.
The 747 amino acid residue isoform 1 has an atro-
phied RapGAP domain at the C-terminus with no other
detectable domains at the N-terminus. The RapGAP
catalytic domain of the human Rap1-GAP protein (PDB:
3BRW) was chosen as reference to infer atrophy. The at-
rophied rat RapGAP domain and the reference human
RapGAP catalytic domain show 30% sequence identity
in the aligned region.
GTPase-activating proteins (GAPs) terminate G-protein
signalling by inducing hydrolysis of bound GTP to GDP
[26]. The human Rap1GAP reference protein comprises
an N-terminal dimerisation and a C-terminal catalytic do-
main and interacts with Rap1B through the catalytic do-
main (Figure 6). Sequence mapping of the rat RapGAP
domain onto the human Rap1-GAP protein (PDB: 3BRW)
indicates structural loss in the catalytic domain (residues
301-414). The catalytic domain is an α/β structure withmixed parallel/antiparallel arrangement of β-strands and a
conserved C-terminal alpha helix. The catalytic centre
comprising Asn290 is close to the nucleotide-binding re-
gion and the protein interface [27,28]. The atrophy does
not affect the catalytic centre or residues involved in
Rap1B interaction suggesting the atrophied domain may
be functional.
Rat RapGAP protein isoform 2 (906 amino acids) and
isoform 3 (2,035 amino acids), however, show no signs
of atrophy, suggesting exon loss mediated by alternative
splicing as a probable mechanism for the observed atro-
phy in isoform 1.
Upstream domain-bounded atrophy
Of the 125 cases of upstream domain-bounded atrophy
identified by our pipeline none were confirmed as true
atrophy events.
Downstream domain-bounded atrophy
2-hydroxyacid dehydrogenase, NAD binding domain
(Pfam: PF02826)
The 2-hydroxyacid dehydrogenase NAD-binding (2-Hacid_
dh_C) domain of Staphylococcus aureus PurK (UniProt:
A6QFS4) (Figure 7A) shows an atrophy score of 0.23.
2-Hacid_dh_C domains are found in dehydrogenases
and oxidoreductases among prokaryotes and eukaryotes.
Bacterial PurK and PurE are involved in the two-step
Figure 6 C-terminal end-bounded atrophy: Ral-GTPase-activating protein domain. The reference protein human Rap1-GAP and its interaction with
Rap1B (green) bound to GDP (magenta) (PDB: 3BRW) is shown. The dimerisation domain (grey) is not involved in interaction with Rap1B. The
region of atrophy of rat RapGAP domain mapped onto the reference structure is shown in orange (residues 301-414). The atrophied catalytic
domain (blue) retains residues involved in catalysis or protein-interaction (grey sticks).
Figure 7 Downstream domain-bounded atrophy: 2-hydroxyacid dehydrogenase, NAD-binding domain. 2-Hacid_dh_C domains from (A) Staphylococcus
aureus PurK (PDB: 3ORQ) and (B) Lactobacillus jensenii D-lactate dehydrogenase (PDB: 4PRL) (C) Superposition of S. aureus and L. jensenii 2-Hacid_dh_C
domains shows the atrophied region (orange, residues 225-298) at the C-terminus. The reverse Rossmann-fold binding motif, GXXGXG, is conserved in
both 4PRL (light pink) and 3ORQ (magenta). Note that the catalytically important Histidine (grey) that interacts with the nicotinamide moiety of NAD
(gold) at the C-terminus is absent in 3ORQ.
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carboxy-5-aminoimidazole ribonucleotide [29].
The reference 2-Hacid_dh_C domain from Lactobacillus
jensenii D-lactate dehydrogenase (PDB: 4PRL) adopts a
Rossmann fold with six parallel β-strands bound to
NAD [30] (Figure 7B). The S. aureus (PDB: 3ORQ) 2-
Hacid_dh_C domain adopts a partial Rossmann fold
and have an additional alpha helix (α2) and β-strand
(β3) insertion [29].
Structural superposition on 4PRL indicates a partial
domain at the C-terminus of 3ORQ (Figure 7C). The
atrophied domain with four parallel β-strands and four
α-helices superimposes well onto the N-terminus of
4PRL, with β-strands β2-β1-β4 aligning on β2-β1-β3 of
the reference domain, respectively, but has no structur-
ally equivalent residues for β4-β6 of the reference do-
main (residues 225-298).
It could also be seen that despite atrophy at the C-
terminus, the domain retains the ‘reverse’ Rossmann fold
motif (GXXGXG) on the loop, at the N-terminus, con-
necting β1 with α1. This binding motif and other inter-
action sites are conserved and are at structurally
equivalent locations (3ORQ: 16-21, 38-41) compared to
the NAD bound 2-Hacid_dh_C of L. jensenii (4PRL:
153-158, 175-178) and might bind to the adenine moiety,
however other residues interacting with the nicotinamide
moiety at the C-terminus (4PRL: Asp259 and His295) are
absent. His295 located near the nicotinamide ring is
thought to be catalytically important [30,31] but is absent
in the atrophied domain. The 2-Hacid_dh_C domain of
Bacillus anthracis (UniProt: C3PBM5, PDB: 3Q2O) also
shows similar atrophy.
RNase_E_G domain (Pfam: PF10150)
The RNase E domain of Pyrococcus furiosus RNA-
binding protein AU-1 (UniProt: Q8U4Q7) shows atro-
phy at the C-terminus with a score of 0.19.
The P. furiosus RNA-binding protein is a large oligo-
meric complex that binds specifically to AU-rich RNA
sequences and may be involved in RNA metabolic pro-
cesses [32]. The RNA-binding protein AU-1 has a large
conserved N-terminal RNase E domain, which shares 25%
sequence similarity with E. coli RNase E [32], and a C-
terminal domain of unknown function DUF402. There are
no experimental structures available of the P. furiosus RNase
E domain and therefore the region of atrophy was inferred
through sequence mapping onto the reference structure.
The E. coli RNase E large domain (PDB: 2C0B) is a large
multi-domain structure comprising four domains: S1, 5’
sensing region, RNase H and DNase I [33]. Mapping of
the P. furiosus RNase E large domain sequences on to the
E. coli RNase E reference domain shows the region of
atrophy corresponds to the C-terminus of the DNase I
domain (residues 339-393) (Figure 8).The DNase I domain has an α/β arrangement of two
α-helices and an antiparallel β-sheet with six antiparallel
β-strands in the order β1–2–3–4–6–5. The DNase I domain
is the catalytic centre of the complex with active sites
Asp303 and Asp346 present on β3 and β4, respectively
[33]. Asp303 and Asp346 coordinate a Magnesium ion,
which, through nucleophilic attack, cleaves the scissile
phosphate on the RNA backbone [33]. Pairwise se-
quence alignment indicates E. coli and P. furiosus RNase
E large domains share 14% sequence identity and atro-
phy at the C-terminus of the DNase I domain results in
the loss of one of the active site residues, Asp346. How-
ever, a more accurate multiple sequence alignment of
the domain family indicates that both catalytic residues
may be present resulting in a potentially functional
domain.
The E. coli RNase E catalytic domain is a tetrameric
complex formed by a dimer-of-dimers, where the dimer
interface of this complex is largely mediated by the
interaction of DNase I domains [34], however, P. furiosus
RNA-binding protein AU-1 forms a homo-oligomeric
complex that is mainly trimeric [32]. The atrophy of
DNase I sub-domain and the presence of a much larger
C-terminal domain DUF402, compared to the E. coli
RNase E small domain, is thought to cause the differ-
ence in the oligomerisation of the complex.
Within-domain atrophy
Glycosyl hydrolase family 10 (Pfam: PF00331)
The Glycosyl hydrolase family 10 (Glyco_hydro_10) do-
main of Cryptococcus albidus Endo-1,4-beta-xylanase
(UniProt: P07529) is found with a within-domain atro-
phy score of 0.24.
Xylanase are found in bacteria, fungi and other mi-
crobes [35,36], which degrade hemicellulose by breaking
down beta-1,4-xylan into xylose. C. albidus endo-1,4-
beta-xylanase is an inducible extracellular enzyme with
xylobiose as its natural inducer [37].
The Glyco_hydro_10 domain of Thermotoga petro-
phila endo-1,4-beta-xylanase reference protein (PDB:
3NJ3) folds into a TIM-barrel structure [38]. Sequence
mapping onto the reference domain indicates a loss of
β-strand β4 and two core alpha helices, α3 and α4
(residues 110-176) (Figure 9). Atrophy of the C. albidus
Glyco_hydro_10 domain would result in the loss of one
of the active sites Glu150, which is present on β4 along
with Asn149, which interacts with the ligand xylobiose.
It has been shown that C. albidus endo-1,4-beta-
xylanase is inefficient in degrading xylobiose and hy-
drolyses xylotriose at very slow rates although longer
substrates such as xylotetraose are hydrolysed [37,39]. It
is surprising that the loss of one of the catalytic residues
Glu150 could still make the enzyme functional, albeit
with a reduced efficiency. Other open TIM-barrels
Figure 8 Downstream domain-bounded atrophy: RNase E large domain. The E. coli RNase E large domain bound to a single strand RNA (yellow)
(PDB: 2C0B). The large domain comprises four different sub-domains. The atrophied region of P. furiosus RNase E large domain (orange, residues
339-393), inferred through sequence mapping, corresponds to nearly half of the DNase I sub-domain. The active site residues involved in cleaving
RNA are shown as sticks (grey) coordinating a Magnesium ion. Missing loop regions are represented as dashed lines.
Figure 9 Within-domain atrophy: Glycosyl hydrolase family 10. The Glycosyl hydrolase family 10 domain of Thermotoga petrophila endo-1,4-beta-xylanase
reference protein bound to xylobiose (pink) (PDB: 3NJ3) folds into a TIM-barrel structure. The atrophied region of C. albidus, inferred through sequence
mapping, comprises structural elements β4, α3 and α4 (orange, residues 110-176) and would lose one of the active site residues Glu150 (grey).
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served in the C-terminal domains of yeast nicotinate
phosphoribosyltransferase (PDB: 1VLP) and Pyrococcus
furiosus Nicotinate-nucleotide pyrophosphorylase (PDB:
2I14). The hydrophobic cores of these partial TIM-
barrels are buried by interactions with their N-terminal
domains. It would be very interesting to see the struc-
ture of C. albidus endo-1,4-beta-xylanase to better
understand how the atrophy event is compensated for.
Conclusions
Proteins evolve by a number of different mechanisms
that lead to changes in sequence, structure and function.
Events such as domain gain or loss have been extensively
studied in terms of evolution of prokaryotic and
eukaryotic genomes [40,41], other minor events such as
gain or loss of secondary structural elements, which
cause structural variations in the domain, are less well
studied. Domain loss has been observed as a major event
during eukaryotic evolution and interestingly hints at an
inverse trend with organismal complexity [40]. Unlike
domain loss wherein a complete domain is absent, we
have investigated events of significant structural loss oc-
curring in a domain, by analysing variation of domain
boundaries across 14,831 domain families in Pfam 27.0.
Domain atrophy events were classified into five groups
based on the location of the domain within the protein
and the region of atrophy in the domain. Domain atro-
phy events are found to be rare accounting for only a
small fraction (0.06%) of the total domain instances ana-
lysed. One of the reasons for such rare occurrence is
that significant loss of structural elements would usually
be detrimental for domain stability. A large number of
factors such as hydrophobic [42] and electrostatic inter-
actions [43] influence the native fold and stability of the
domain, and unlike domain elaborations, loss of core
structural elements involved in such interactions would
not be favourable.
An intriguing aspect of atrophied domains is the ener-
getics of their folds. Deletions or insertions of individual
residues can significantly influence the overall energetics
of the fold [44]. Deletion of structural elements, as ob-
served in atrophied domains, would contribute to sig-
nificant changes in the energetics compared to the
native fold and as such warrant major compensatory
mechanisms to stabilise fold. It was shown that hydro-
phobic contacts at the domain-domain interface stabilise
the otherwise unstable domains in a multi-domain
protein [45]. Formation of multimeric complexes or
domain-domain interactions may serve as one of the
compensatory mechanisms for stabilising atrophied do-
mains as observed in the cases of P. leiognathi bacterial
luciferase domain and the AMP-binding domain of B.
cenocepacia.Atrophied domains should have incomplete/partial
folds, but the converse may not be true. For example,
the histidine biosynthesis pathway enzymes HisA and
HisF consist of two copies of a (β/α)4 half-barrel [46]. It
has been proposed that the complete (β/α)8 TIM-barrel
may have evolved from duplication and gene fusion of
an ancestral (β/α)4 half-barrel [46].
An important issue is to understand how domain atro-
phy events arise. Mutational events such as a mutation
to a premature stop codon could lead to domains with
atrophy at the C-terminus. While the creation of a new
downstream start codon could lead to domains with at-
rophy at the N-terminus. Other mechanisms such as
exon loss or deletion could additionally lead to atrophy
within the domain. We observe a large number of do-
main atrophy cases at the termini of proteins: N-termini
(n = 40) and C-termini (n = 26), compared to atrophy
cases within a protein. We see just four cases of atro-
phies within a domain, and we only see five cases of at-
rophy events that are bounded by other domains, and
hence also occur within the protein. It is unclear
whether this is a reflection of the true proportions or
simply due to our methodology. Alternative splicing pro-
vides one possible mechanism that enables an organism
to explore atrophied domain sequence space while still
retaining a functional copy [47]. Analysis of splice vari-
ants from the ENCODE dataset indicates a large number
of splice sites occur within functional domains [48], sug-
gesting a plausible mechanism for domain atrophy. It
was previously shown that alternative splicing events in
human result in fewer partial domains than expected
[49]. These partial domains were reported to affect a sig-
nificant number of functional sites [49] and may trans-
late into proteins with altered structures and functions
[47,48]. Strong selection pressure may also play a role in
the evolution of atrophied domains, selecting only atro-
phied domains with an important structural or func-
tional role for the organism that must be kept.
Unfolded proteins or misfolded proteins are targeted
by protein degradation machinery by recognising their
solvent exposed hydrophobic residues. Although no
clear experimental data are available from known cases
of atrophied domains on their possible mechanisms to
evade recognition and degradation by the protein deg-
radation machinery, we speculate atrophied domains
escape unfolding and degradation by burying their ex-
posed solvent-accessible areas through dimerisation or
complex formations.
Disordered or transiently unfolded regions are known to
fold cooperatively upon contact with their binding part-
ners [50] and evade degradation until then. Chaperones,
such as BiP, maintain unfolded or misfolded proteins in a
folding-competent state [51]. We think atrophied domains
with solvent exposed hydrophobic residues may be
Prakash and Bateman Genome Biology  (2015) 16:88 Page 11 of 15similarly protected by chaperones until folded stably upon
complex formation.
We observe that domain atrophy is a very rare event
compared to domain loss or elaborations. Our analyses
of a subset of protein sequences, with protein existence
value of 1, defined by UniProt, indicates only a minute
fraction of domains exhibit atrophy. An independent
analysis [13] of a broader sequence space also corrobo-
rates the findings. A large percentage of the protein do-
mains in Pfam, annotated as partial domains, are largely
found to be profile-HMM alignment or sequence anno-
tation artefacts [13]. Our work has greatly increased the
number of known atrophy cases. As identified by Triant
and Pearson it is very difficult to identify true cases of
domain atrophy from artefacts. Availability of high qual-
ity data with refined protein domain models and se-
quences, together with experimental structures of such
atrophied domains, can further shed light on domain at-
rophy and its role in evolution of protein domains. Our
work presents potential domain atrophy cases for further
experimentation that will lead to an improved under-
standing of how proteins tolerate extreme mutations.Methods
Data
To identify potential cases of domain atrophy we use
matches of the UniProt sequence database (release
2012_06) against the profile-HMM models from the
Pfam database release 27.0 [52]. This set of matchesFigure 10 Calculation of domain atrophy score. Domain atrophy score is t
(L). (A) N-terminal end-bounded atrophy. (B) C-terminal end-bounded atro
domain-bounded atrophy. (E) Within-domain atrophycontains 28,738,352 Pfam-A protein domain instances
across 14,831 families in 18,523,877 protein sequences.
Atrophy score
To determine which domains may be cases of atrophy
we calculate a measure called the Atrophy Score (AS) at
both the N- (ASN) and C-terminal (ASC) boundaries of
each domain instance. Figure 10 shows a schematic rep-
resentation of the parameters used in calculating domain
atrophy score. The equations used to calculate the atro-
phy score are shown below:
ASN ¼ DN– dNð Þ=L
ASC ¼ DC– dCð Þ=L
Where, ASN is the atrophy score at the N-terminus of
the domain, DN is the number of unmatched HMM
match states at the N-terminus of the domain, dN is the
inter-domain distance or domain interval that is the
number of amino acid residues between the domain and
its adjacent upstream domain or the sequence start site
in the case of an N-terminal domain, and L is the HMM
model length of the domain family. Similarly ASC, DC
and dC correspond to atrophy score, the number of un-
matched HMM match states and the inter-domain dis-
tance of the C-terminus of the domain, respectively.
Instances of within-domain atrophy can be identified
in cases where the profile-HMM matches to a single do-
main have been split into two profile-HMM matches,
with the first corresponding to the N-terminal part ofhe ratio of missing region (D – d) of the domain to its model length
phy. (C) Upstream domain-bounded atrophy. (D) Downstream
Figure 11 Failure modes of the pipeline. (A) Incorrect gene
prediction or partial sequence: sequence fragment or incorrect gene
prediction could lead to events that look like domain atrophy, example:
Aldo/keto reductase family (UniProt: P43546, Pfam: PF00248) (B)
Tandem repeat: a tandem repeat is distinguished from single
domain instances that are split/predicted in two parts, by considering
its HMM match coordinates; for a tandem domain instances the
downstream domain start-HMM-match state is less than the upstream
domain end-HMM-match state, example: Peroxidase (Uniprot: A0QXX7,
Pfam: PF00141). (C) Nested domain: this architecture results in an
atrophy score greater than 1 for domain hosting nested domain(s),
example: Peptidase_M20 (UniProt: A0Z6B3, Pfam: PF01546) (D)
Unmatched domain region: missing region of the domain containing
a nested domain, example: Lon_C (UniProt: A4ILZ1, Pfam: PF05362)
(E) Multi-domain family: a single-domain architecture comprising more
than one domain. (F) Domain overlap, example: 4Fe-4S single cluster
domain (UniProt: A6L094, Pfam: PF13353).
Prakash and Bateman Genome Biology  (2015) 16:88 Page 12 of 15the domain and the second corresponding to the C-
terminal part of the domain. We can distinguish these
cases from tandem repeats by considering the HMM
match states of each domain. The start HMM-match
state of the downstream domain is greater than the end
HMM-match state of the upstream domain in cases of
split domains. The computation of within-domain atro-
phy score (ASW) is similar to ASN.
ASW ¼ DW– dWð Þ=L
Where DW is the number of unmatched HMM match
states within the domain, dW is the domain interval
within the domain and L is the HMM model length of
the domain family.
Alignment co-ordinates of each domain are considered
to calculate the inter-domain interval. An intuitive de-
scription of the Atrophy Score would be that a score of
0.33 means that one-third of the length of the domain
has been lost to domain atrophy.
We classified domain atrophy events into five types,
based on the domain location (architecture) in the protein
and the region of atrophy in the domain: (1) N-terminal
end-bounded atrophy: structural loss at the N-terminal
region of the N-terminal domain; (2) C-terminal end-
bounded atrophy: structural loss at the C-terminal region
of the C-terminal domain; (3) Upstream domain-bounded
atrophy: structural loss at the N-terminal region of an
inner domain, also including the N-terminal region of the
C-terminal domain; (4) Downstream domain-bounded at-
rophy: structural loss at the C-terminal region of an inner
domain, also including the C-terminal region of the N-
terminal domain; and (5) Within-domain atrophy: struc-
tural loss within the domain.
Filtering
Initial results from applying the atrophy score to all
UniProt proteins showed that there were numerous
common failure modes (Figure 11) that would mask
our ability to find genuine domain atrophy events.
Therefore, we applied a set of filters to reduce the num-
ber of false positive matches with high atrophy scores.
Of a total of 23,193,494 sequences in the database,
18,523,877 sequences, which have at least one Pfam-A
domain instance, were used in the analysis. Initial filter-
ing was applied to exclude domain models from se-
quences with protein existence (PE) levels of 2 to 5.
These are enriched in gene prediction errors and frag-
ment proteins. This reduced the number of sequence
considered from 18,523,877 to 77,305. Proteins with a
protein existence level of 1 have clear experimental evi-
dence for the existence of the protein from Edman se-
quencing, mass spectrometry, X-ray, NMR or other
experimental evidence. Although not strictly a measureof protein sequence quality these proteins usually have
highly accurate protein sequences. We also removed se-
quences annotated as fragments in UniProt, which fur-
ther reduced the set of sequences considered from
77,305 to 75,435.
Adjacent domains that are of the same clan, similar to
figure 11B, could lead to ambiguous domain boundary
assignments at the interval and hence such cases were
filtered out to avoid detecting false atrophy events. The
resulting final-set comprising 114,303 domain instances
from 75,435 sequences were included in the analysis.
Perl scripts were run to calculate atrophy scores across
the set of domains. Domain instances with an atrophy
score of 0.15 or more were further investigated.Manual inspection
Domain instances that were obtained after applying the
above filters were then selected for manual inspection.
Only those domains that had an atrophy score of 0.15 or
above were checked manually for identification of false
positives. We checked each potential domain atrophy
case for evidence of any of the following failure modes
Table 2 Cases of failure modes or false positives
Types of failure modes or false positives Number of instances
Total 1,287
Gene prediction error 9







No other reference structure available 27
Complete structural domain 234
Domain instances with atrophy scores between 0.15 and 1 that were manually
checked and classified into one of the failure modes or false positives.
Prakash and Bateman Genome Biology  (2015) 16:88 Page 13 of 15(see Figure 11): (1) Gene prediction errors: We checked
whether the missing part of a domain was to be found
in an adjacent gene or due to an incomplete gene pre-
diction; (2) Nested domains: We checked whether a high
atrophy score was due to a domain nesting within an-
other. These were considered as false positives; (3)
Multi-domain families: Due to incorrect Pfam domain
definitions some Pfam domains actually correspond to
multiple structural domains that can be found independ-
ently. We checked the structure of each Pfam family to
confirm whether this was the cause of a high atrophy
score; (4) Small domains: Domains of length less than 30
amino acid residues were not considered since atrophy
score of 0.15 and above of small domains correspond to
loss of a single secondary structural element or a part
thereof, which is not considered true atrophy; (5) Circu-
lar permutations: While circular permuted domains are
complete domains, the rearrangement of domain HMM
start-site and HMM end-site with respect to their do-
main HMM-model would result in misidentification of
such cases as domain atrophies; (6) Short repeats:
Domains composed of tandem structural motifs, such as
β-propeller, β- or α-helix, are made of short repeating
sequence motifs were considered as false positives.
Addition or removal of repeats is often tolerated in
terms of protein mutation; and (7) Disordered domains:
Inferring domain atrophy among intrinsically disordered
protein domains is not straightforward mainly owing to
their lack of native ordered tertiary structure and such
cases were considered false positives.
Apart from the above failure modes domain atrophy
cases whose structures were theoretically modelled or
had no other reference structures in the family to com-
pare with were also treated as failure modes. Other cases
of complete structural domains but identified as domainatrophy were treated as false positives. Table 2 lists the
occurrences of different types of failure modes.
From a total of 1,636 domain instances, with atrophy
scores between 0.15 and 1, which were manually
checked, 1,287 domain instances were classified as fail-
ure modes or false positives. The positive predictive
value (PPV) of our method is 0.055.
Visualisation of structures
Structures were visualised with Chimera [53]. Where ex-
perimental structures of atrophied domains were not
available, the shortest full-length domain structure
within the domain family was chosen as the reference.
The extent of domain atrophy was then inferred by a
pairwise sequence alignment guided mapping of un-
aligned sequence regions onto the reference structure.
Instances of putative domain atrophy where no full-
length reference structure was available for the family
were not considered further.
Phylogenetic analysis
Evolutionary information was inferred from phylogenetic
trees constructed from multiple sequence alignment of
domain family seed sequences and homologous sequences
from a JackHMMER search [54]. A non-redundant set of
sequences of 90% identity or less was aligned with Mafft
[55] with default settings. Alignments were visualised with
Belvu [56] and phylogenetic trees constructed using the
neighbour-joining method present in Belvu using default
parameters.
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